Acute poisoning: Understanding 90% of cases in a nutshell

Postgraduate Medical Journal

Volumn 81, Issue 954, 2005, Pages 204-216

  Greene, S L ^a,b   Dargan, P I ^b   Jones, A L ^b  

^a Medical Toxicology Unit   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4 METHYLPYRAZOLE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ACTIVATED CARBON; ALCOHOL; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDOTE; ATROPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; COBALT EDETATE; COCAINE; CODEINE; CYANIDE; CYPROHEPTADINE; DANTROLENE; DEFEROXAMINE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DIAZEPAM; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; ETHYLENE GLYCOL; FLUOXETINE; GLUCAGON; GLUCOSE; HEAVY METAL; HYDROXOCOBALAMIN; IBUPROFEN; INSULIN; IPECAC; IRON; LORAZEPAM; MACROGOL; METHANOL; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OPIATE; ORGANOPHOSPHATE; PARACETAMOL; PAROXETINE; PHYTOMENADIONE; SALICYLIC ACID DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA DERIVATIVE; TEMAZEPAM; THIAMINE; THIOSULFATE; TRICYCLIC ANTIDEPRESSANT AGENT; ZOPICLONE;

ACCIDENT; AGITATION; BLOOD PRESSURE; BODY TEMPERATURE; BODY WEIGHT; BREATHING RATE; CARDIOVERSION; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG OVERDOSE; DRUG URINE LEVEL; EMERGENCY WARD; HEART ARREST; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; HYPERTHERMIA; HYPOGLYCEMIA; HYPOTENSION; INGESTION; INTESTINE LAVAGE; MORTALITY; PSYCHOLOGIC ASSESSMENT; RESUSCITATION; REVIEW; RISK FACTOR; SEIZURE; STOMACH LAVAGE; UNITED KINGDOM;

ACETAMINOPHEN; ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIDOTES; BENZODIAZEPINES; CHILD; DIAGNOSTIC TESTS, ROUTINE; EMERGENCY TREATMENT; GASTRIC LAVAGE; HUMANS; NARCOTICS; POISONING; RISK FACTORS; SALICYLATES; SEROTONIN UPTAKE INHIBITORS;

EID: 17444367370     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.024794     Document Type: Review

References (205)

1. Townsend E, Hawton K, Harriss L, et al. Substances used in deliberate self-poisoning 1985-1997: trends and associations with age, gender, repetition and suicide intent. Soc Psychiatry Psychiatr Epidemiol 2001;36:228-34.
2. WHO/EURO. Results of the WHO/EURO multicentre study on parasuicide. Acta Psychiatr Scond 1996;93:327-38.
3. Michel K, Ballinari P, Bille-Brahe U, et al. Methods used for parasuicide: results of the WHO/EURO Multicentre Study on Parasuicide. Soc Psychiatry Psychiatr Epidemiol 2000;35:156-63.
4. Schmidtke A, Bille-Brahe U, Deleo D, et al. Attempted suicide in Europe: rates, trends, and sociodemographic characteristics of suicide attempters during the period 1989-1992. Acta Psychiatr Scand 1996;93:327-38.
5. Gunnell D, Ho D, Murray V. Medical management of deliberate drug overdose: a neglected area for suicide prevention? Emerg Med J 2004;21:35-8.
6. Watson WA, Litovitz TL, Rodgers GC, et al. 2002 Annual report of the American Association of Poison Control Centres Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421.
7. Flanagan RJ, Rooney C. Recording acute poisoning deaths. Forensic Sci Int 2002;128:3-19.
8. Hawton K, Fagg J, Simkin S, et al. Trends in deliberate self-harm in Oxford, 1985-1995. Implications for clinical services and the prevention of suicide. Br J Psychiatry 1997;171:556-60.
9. Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ 2001;322:1203-7.
10. Camidge DR, Wood RJ, Bateman DN. The epidemiology of self-poisoning in the UK. Br J Clin Pharmacol 2003;56:613-19.
11. Flanagan RJ, Jones AL. Antidotes. London: Taylor-Francis, 2001.
12. Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway Sarin attack disaster management. Part 2; Hospital report. Acad Emerg Med 1998;6:618-24.
13. Albertson TE, Dawson A, de Latorre F, et al. American Heart Association; International Liaison Committee on Resuscitation. TOX-ACLS: toxicologic-oriented advanced cardiac life support, Ann Emerg Med 2001;37:S78-90.
14. Mokhlesi B, Leikin JB, Murray P, et al. Adult toxicology in critical care: Part II: specific poisonings. Chest, 2003 Mar, 123:897-922.
15. Jones AL, Dargan PI. Churchill's pocket book of toxicology. London: Churchill Livingstone, 2001.
16. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMA/RPSGB, Mar, 2004.
17. Callaham M, Schumaker H, Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther 1988;245:216-20.
18. Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987;9:135-41.
19. Wech R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000;25:154-60.
20. Blum K, Eubanks JD, Wallace JE, et al. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 1976;9:427-34.
21. Derlet RW, Albertson TE, Rice P. The effect of haloperidol in cocaine and amphetamine intoxication. J Emerg Med 1989;7:633-7.
22. Bosse GM. Antidiabetic and Hypoglycaemic Agents. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:858-9.
23. Graudins A, Linden CH, Ferm RP. Diagnosis and treatment of sulfonylurea-induced hyperinsulinemic hypoglycemia. Am J Emerg Med 1997;15:95-6.
24. Clarke SF, Dargan PI, Jones AL. Naloxone-a systematic review. Emerg Med J (in press).
25. Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995;274:562-9.
26. Schrier RW, Henderson HS, Tisher CC, et al. Nephropathy associated with heat stress and exercise. Ann Intern Med 1967;67:356-76.
27. Vertel RM, Knochel JP. Acute renal failure due to heat injury. An analysis of ten cases associated with a high incidence of myoglobinuria. Am J Med 1967;43:435-51.
28. Greene SL, Dargan PI, O'Connor N, et al. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 2003;21:121-4.
29. Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. Ann Intern Med 1970;73:81-5.
30. Hollander JE, Hoffman RS. Cocaine. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:1004-17.
31. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-19.
32. Mc Caron MM, Boettger ML, Peck JJ. A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatry 1982;43:381-2.
33. Greene SL, Dargan PI, Shin GY, et al. Doctors and nurses estimation of the weight of patients-a source of systematic error? J Toxicol Clin Toxicol 2004;42:611-15.
34. Dargan PI, Ladhani S, Jones AL. Measuring plasma paracetamol concentrations in all patients with drug overdose or altered consciousness: does it change outcome? Emerg Med J 2001;18:178-82.
35. Hartington K, Hartley J, Clancy M. Measuring plasma paracetamol concentrations in all patients witti drug overdoses; development of a clinical decision rule and clinicians willingness to use it. Emerg Med J 2002;19:408-11.
36. Wood DM, Dargan PI, Jones AL. Measuring plasma salicylate concentrations in all patients with drug overdose or altered consciousness: is it necessary? Emerg Med J (in press).
37. Rainley PM. Laboratory principles and techniques for evaluation of the poisoned or overdosed pateint. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:69-93.
38. Baselt RC. Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications, 2002:247-53.
39. National Poisons Information Service; Association of Clinical Biochemists. Laboratory analyses for poisoned patients: joint position paper. Ann Clin Biochem 2002;39:328-39.
40. Wu AH, McKay C, Broussard LA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem 2003;49:357-79.
41. Dawson AH, Whyte IM. Evidence in clinical toxicology: the role of therapeutic drug monitoring. Ther Drug Monit 2002;24:159-62.
42. Baselt RC. Disposition of toxic drugs and chemicals in man. 6th ed. Foster City, CA: Biomedical Publications, 2002:472-5, 707-10.
43. American Academy of Clinical Toxicology and European Association of Poisons Control Centres and Clinical Toxicologists. Position statement: Single-dose activated charcoal. J Toxicol Clin Toxicol 1997;35:721-41.
44. American Academy of Clinical Toxicology and European Association of Poisons Control Centres and Clinical Toxicologists. Position statement: ipecac syrup. J Toxicol Clin Toxicol 1997;35:699-709.
45. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol 1999;37:731-51.
46. American Academy of Clinical Toxicology and European Association of Poisons Control Centres and Clinical Toxicologists. Position statement: gastric lavage. J Toxicol Clin Toxicol 1997;35:711-19.
47. American Academy of Clinical Toxicology and European Association of Poison Control Centres and Clinical Toxicologists. Position statement: whole bowel irrigation. J Toxicol Clin Toxicol 1997;35:753-62.
48. Thakore S, Murphy N. The potential role of prehospital administration of activated charcoal. Emerg Med J 2002;19:63-5.
49. Karim A, Ivatts S, Dargan PI, et al. How feasible is it to conform to the European guidelines on the administration of activated charcoal within one hour of overdose? Emerg Med J 2001;18:390-2.
50. Wolseley BA, McKinney PE. Does transportation by ambulance decrease time to gastrointestinal decontamination after overdose? Ann Emerg Med 2000;35:579-84.
51. Bond GR. The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med, 2002 Mar, 39:273-86.
52. Neuvonen PJ, Olkkola KT. Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses. Med Toxicol Adverse Drug Exp 1988;3:33-58.
53. Saetta JP, March S, Gaunt ME. Gastric emptying procedures in the self poisoned patient: are we forcing gastric content beyond the pylorus? J R Soc Med 1991;84:274-6.
54. Eddleston M, Juszczak E, Buckley N. Does gastric lavage really push poisons beyond the pylorus? A systematic review of the evidence. Ann Emerg Med 2003;42:359-64.
55. Thompson AM, Robins JB, Prescott LF. Changes in cardiorespiratory function during gastric lavage for drug overdose. Hum Exp Toxicol 1987;6:215-18.
56. Tenenbein M. Whole bowel irrigation as a gastrointestinal decontamination procedure after acute poisoning. Med Toxicol 1988;3:77-84.
57. Morgan AG, Polak A. The excretion of salicylate in salicylate poisoning. Clin Sci 1971;41:475-84.
58. Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol 2004;42:1-26.
59. Pond SM. Diuresis, dialysis, and hemoperfusion. Indications and benefits. Emerg Med Clin North Am 1984;2:29-45.
60. Scharman EJ. Methods used to decrease lithium absorption or enhance elimination. J Toxicol Clin Toxicol 1997;35:601-8.
61. Jacobsen D, Wilk-Larsen E, Bredesen JE. Haemodialysis or haemoperfusion in severe salicylate poisoning? Hum Toxicol 1988;7:161-3.
62. Hootkins R Sr, Lerman MJ, Thompson JR. Sequential and simultaneaus "in series" hemodiolysis and hemoperfusion in the management of theophylline intoxication. J Am Soc Nephrol 1990;1:923-6.
63. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. J Toxicol Clin Toxicol 2002;40:415-46.
64. Barceloux DG, Krenzelok EP, Olsen K, et al. American Academy of Clinical Toxicology Practice guidelines on the treatment of ethylene glycol poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol 1999;37:537-60.
65. Park GD, Spector R, Roberts RJ, et al. Use of hemoperfusion for treatment of theophylline intoxication. Am J Med 1983;74:961-6.
66. Cutler RD, Forland SC, John PG. Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Ann Rev Pharmacol Toxicol 1987;27:169-91.
67. Bar-Oz B, Levichek Z, Koren G. Medications that can be fatal for a toddler with one tablet or teaspoonful: a 2004 update. Pediatric Drugs 2004;6:123-6.
68. Koren G. Medications which can kill a toddler with one tablet or teaspoon. J Toxicol Clin Toxicol 1993;31:407-13.
69. Liebelt EL, Shannon MW. Small doses, big problems: a selected review of highly toxic common medications. Pediatr Emerg Care 1993;9:292-7.
70. Anderson BJ, Holford NHG, Armishaw JC. Predicting concentrations in children presenting with acetaminophen overdose. J Pediatr 1999;135:290-5.
71. Bond GR, Krenzelok EP, Normann SA. Acetaminophen ingestion in childhood-cost and relative risk of alternative referral strategies. J Toxicol Clin Toxicol 1994;32:513-25.
72. Mohler CR, Nordt SP, Williams SR, et al. Prospective evaluation of mild to moderate pediatric acetaminophen exposures. Ann Emerg Med 2000;35:239-44.
73. Caravati EM. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity. J Toxicol Clin Toxicol 2000;38:291-6.
74. Litovitz T, Schmitz BF. Ingestionn of cylindrical and button batteries: an analysis of 2382 cases. J Pediatr 1984;89:747-57.
75. Kulig K, Rumack C, Rumack B, et al. Disk battery ingestion-elevated urine mercury levels and enema removal of battery fragments. JAMA 1983;249:2502-4.
76. Singalet D, Lees G. Tracheosophageal injury secondary to disk battery ingestion. J Pediatr Surg 1988;23:996-8.
77. Wilson JA, Phillips EM. Endoscopic retrieval of a miniature battery. Gut 1985;26:215.
78. Rumack Cm, Rumack BH. Battery Ingestions. Pediatrics 1992;89:771-2.
79. Liovitz T, Butterfield AB, Holloway RR, et al. Battery ingestion: assessment of therapeutic modalities and battery discharge state. J Pediatr 1984;105:868-73.
80. Litovitz TL, Flagler SL, Manoguerra AS, et al. Recurrent poisonings among pediatric poisoning victims. Med Toxicol 1989;4:381-6.
81. Demorest RA, Posner JC, Osterhoudt KC, et al. Poisoning prevention education during emergency department visits for childhood poisoning. Pediatr Emerg Care 2004;20:281-4.
82. Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ 1996;313:1417-18.
83. Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J 2002;19:202-5.
84. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ 1979;2:1097-100.
85. Jones AL. Recent advances in the management of late paracetamol poisoning. Emergency Medicine (Australia) 2000;12:14-21.
86. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Tox 1998;36:277-85.
87. Prescott LF. Paracetamol overdosage: pharmacological considerations and clinical management. Drugs 1983;23:290-314.
88. NPIS. Management of acute paracetamol poisoning, Guidelines agreed by the UK National Poisons Information Service 1998. (Supplied to Accident and Emergency Centres in the United Kingdom by the Paracetamol Information Centre in collaboration with the British Association for Accident and Emergency Medicine). London: NPIS, 1998.
89. Prescott LF. Paracetamol (acetaminophen). A critical bibliographic review. London: Taylor and Francis, 1996.
90. Buhl R, Jaffe HA, Holroyd KA. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;ii:1294-8.
91. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-50.
92. Wright N, Prescott LF. Potentiation by previous drug therapy of hepatotoxicity following paracetamol overdose. Scott Med J 1973;18:56-8.
93. Smith JA, Hine ID, Beck P, et al. Paracetamol toxicity: is enzyme induction important? Hum Exp Toxicol 1986;5:383-5.
94. Minton N, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. Hum Exp Toxicol 1988;7:33-4.
95. Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000;49:291-301.
96. Bray GP, Mowat C, Muir DF, et al. The effect of chronic alcohol intake on prognosis and outcome in paracetamol overdose. Hum Exp Toxicol 1991;10:435-8.
97. Buckley NA, Sinivasan J. Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism?: a case for, Drug Saf 2002;25:619-24.
98. Dargan PI, Jones AL. Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism?: a case against, Drug Saf 2002;25:625-32.
99. Buckley NA, Whyte IM, O'Connell DL, et al. Activated chorcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999;37:753-7.
100. Clark RF, Chen R, Williams SR, et al. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. J Toxicol Clin Toxicol 1996;34:163-7.
101. Prescott LF, Park J, Ballantyne A, et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977;ii:432-4.
102. Prescott LF, Roscoe P, Wright N, et al. Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet 1971;i:519-22.
103. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995;346:547-52.
104. Mant TG, Tempowski JH, Volans GN, et al. Adverse reactions to acetylcysteine and effects of overdose. BMJ 1984;289:217-19.
105. Buckley NA, Whyte IM, O'Connell DL, et al. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999;37:753-7.
106. Bailey B, McGuigan MA. Management of anaphylactoid reactions to N-acetylcysteine. Ann Emerg Med 1998;31:710-15.
107. Ho SW, Beilin U. Asthma associated with N-acetylcysteine infusion and paracetamol paisoning: report of two cases. BMJ (Clin Res Ed) 1983;287:876-7.
108. Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol 2001;51:87-91.
109. Appelboam AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J 2002;19:594-5.
110. Vale JA, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning. The use of oral methionine. Arch Intern Med 1981;141:394-6.
111. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-3.
112. Whyte IM, Seldon M, Buckley NA, et al. Effect of paracetamol poisoning on international normalised ratio. Lancet 2003;361:429.
113. Makin A, Williams R. The current management of paracetamol overdosage. Br J Clin Pharmacol 1994;48:144-8.
114. Dargan PI, Jones AL. Acetaminophen poisoning: an update for the intensivist. Crit Care 2002;6:108-10.
115. Hall AH, Smolinskie SC, Conrad FL. Ibuprofen overdose: 126 cases. Ann Emerg Med 1986;15:1308-12.
116. Holpern SM, Fitzpatrick R, Volans GN. Ibuprofen toxicity: a review of adverse reactions and overdose. Adverse Drug React Toxicol Rev 1993;12:107-28.
117. Hall AH, Smolinske SC, Kulig KW. Ibuprofen overdose: a prospective study. West J Med 1988;48:653-6.
118. Balai-Mood M, Proudfoot AT, Critchley J. Mefanamic acid overdose. Lancet 1981;ii:1324-56.
119. Linden CH, Townswend PL. Metabolic acidosis after acute ibuprofen overdose. J Pediatr 1987;111:922-5.
120. Kulling PE, Backman EA, Skagius AS. Renal Impairment after acute diclofenac, naproxen, and sulindac overdoses. Clin Toxicol J Toxicol 1995;33:173-7.
121. Kertesz A. Neurological complications of non-steroidal anti-inflammatory agents. In: Barda I, Koff R, eds. Nonsteroidal Antiinflammatory drugs: a profile of adverse effects. Philadelphia: Hanley and Belfus, 1992:147-55.
122. Dargan PI, Wallace CI, Jones AL. An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J 2002;19:206-9.
123. Brenner BE, Simon RR. Mangement of salicylate intoxication. Drugs 1982;24:335-40.
124. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981;141:364-9.
125. Gabow PA. How to avoid overlooking salicylate intoxication. J Crit Illness 1986;1:77-85.
126. Tenney SM, Miller RM. The respiratory and circulatory action of salicylate. Am J Med 1955;19:498-508.
127. Kaplan E, Kennedy J, David J. Effects of salicylates and other bezoates on oxidative enzymes of the tricarboxylic cycle in rat tissue homogenates. Arch Biochem Biophys 1954;51:47-61.
128. Gaudreault P, Temple AR, Lovejoy FH Jr. The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 1982;70:566-9.
129. Chapman BJ, Proudfoot AT. Adult salicylate poisoning: deaths and outcome in patients with high plasma salicylate concentrations. Q J Med 1989;72:699-707.
130. Danel V, Henry JA, Glucksman E. Activated charcoal, emesis, and gastric lavage in aspirin overdose. BMJ (Clin Res Ed) 1988;296:1507.
131. Hillman RJ, Prescott LF. Treatment of salicylate poisoning with repeated oral charcoal. BMJ (Clin Res Ed) 1985;291:1472.
132. Kirshenbaum LA, Mathews SC, Sitar DS, et al. Does multiple-dose charcoal therapy enhance salicylate excretion? Arch Intern Med 1990;150:1281-3.
133. Proudfoot AT. Toxicity of salicylates. Am J Med 1983;75:99-103.
134. Done AK. Salicylate intoxication: significance of measurements of salicylate in blood in cases of acute intoxication. Pediatrics 1960;26:800-7.
135. Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? BMJ (Clin Res Ed) 1982;285:1383-6.
136. Yip L, Dart RC, Gabow PA. Concepts and controversies in salicylate toxicity. Emerg Med Clin North Am 1994;12:351-64.
137. Todd PJ, Sills JA, Harris F, et al. Problems with overdoses of sustained-release aspirin. Lancet 1981;i:777.
138. Nelson LS. Opioids. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:901-23.
139. Watson WA. Opioid toxicity recurrence after an initial response to naloxone. Clin Toxicol 1998;36:11-17.
140. Goldfrank L, Weisman RS, Errick JK, et al. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15:566-70.
141. Hawton K, Simikin S, Deeks J. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. BMJ 2003;326:1006-8.
142. Lund-Jacobsen H. Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. Acta Pharmacol Toxicol 1978;42:171-8.
143. Stork CM, Reed JT, Fine K, et al. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate-a case report. J Toxicol Clin Toxicol 1995;33:179-83.
144. Hojer J, Braehrendtz S, Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 1989;226:117-22.
145. Greenblatt DJ, Allen MD, Noel BJ. Acute overdose with benzodiazepine derivatives. Clin Pharmacol Ther 1977;21:497-514.
146. Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 1993;163:386-93.
147. Martens F, Koppel C, Ibe K, et al. Clinical experience with the benzodiazepine antagonist flumazenil in suspected benzodiazepine or ethanol poisoning. J Toxicol Clin Toxicol 1990;28:341-56.
148. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with a mixed drug overdose. Ann Pharmacother 1994;28:1347-9.
149. Herd B, Clarke F Herd B, Clarke F. Complete heart block after flumazenil. Hum Exp Toxicol 1991;10:289.
150. Geller E, Crome P, Schaller MD, et al. Risks and benefits of therapy with flumazenil (Anexate) in mixed drug intoxications. Eur Neurol 1991;31:241-50.
151. Amerin R, Leishman B, Bentzinger C, et al. Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology. Med Toxicol Adverse Drug Exp 1987;2:411-29.
152. Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992;14:292-305.
153. Frommer DA, Kulig KW, Marx JA, et al. Tricyclic antidepressant overdose. A review. JAMA 1987;257:521-6.
154. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med 1985;14:1-9.
155. Shannon M. Duration of QRS disturbances after severe tricyclic antidepressant intoxication. J Toxicol Clin Toxicol 1992;30:377-86.
156. Liebelt EL, Francis PD. Cyclic Antidepressants. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:847-64.
157. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 1997;16:374-90.
158. Sasyniulc BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther 1984;231:387-94.
159. Pellinen TJ, Farkkila M, Heikkila J, et al. Electrocardiographic and clinical features of tricyclic antidepressant intoxication. A survey of 88 cases and outlines of therapy. Ann Clin Res 1987;19:12-17.
160. Shannon MW, Merola J, Lovejoy FH Jr. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988;6:439-42.
161. Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol 1986;1:101-21.
162. Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985;313:474-9.
163. Caravati EM, Bossart PJ. Demographic and electrocardiographs factors associated with severe tricyclic antidepressant toxicity. J Toxicol Clin Toxicol 1991;29:31-43.
164. Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995;26:195-201.
165. Hoffman JR. Overdose with cardiotherapeutic agents. Geriatrics 1983;38:51-65.
166. Levitt MA, Sullivan JB, Owens SM, et al. Amitriptyline plasma protein binding: effect of plasma pH and relevance to clinical overdose. Am J Emerg Med 1986;4:121-5.
167. McCabe JL, Cobaugh DJ, Menegazzi JJ, et al. Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison or hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med 1998;32:329-33.
168. Sasyniuk BI, Jhamandas V, Valois M. Experimental amitriptyline intoxication: treatment of cardiac toxicity with sodium bicarbonate. Ann Emerg Med 1986;15:1052-9.
169. Orr DAK, Bramble MG. Tricyclic antideressant poisoning and prolonged external cardiac massage during asystole. BMJ 1981;283:1107-8.
170. Southall DP, Kilpatrick SM. Imipramine poisoning: survival of a child after prolonged cardiac massage. BMJ 1974;4:508.
171. Beaubein AR, Carpenter DC, Mathieu FL. Antagonism of imipramine poisoning by anticonvulsants in the rat. Toxicol Appl Pharmacol 1976;38:1-6.
172. Borys DJ, Setzer SC, Ling LJ, et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992;10:115-20.
173. Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995;26:234-7.
174. Graudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med 1997;15:501-3.
175. Johnsen CR, Hoejlyng N. Hyponatremia following acute overdose with paroxetine. Int J Clin Pharmacol Ther 1998;36:333-5.
176. Personne M, Sjoberg G, Persson H. Citalopram overdose-review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-40.
177. White CM, Hailey RA, Levin GM, et al. Seizure resulting from a venlafaxine overdose. Ann Pharmacother 1997;31:178-80.
178. Zhalkovsky B, Walker D, Bourgeois JA. Seizure activity and enzyme elevations after venlafaxine overdose. J Clin Psychopharmacol 1997;17:490-1.
179. Banham NDG. Fatal venlafaxine overdose. Med J Aust 1998;169:445-8.
180. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18:309-13.
181. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 2003;96:369-74.
182. Chan BS, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust 1998;169:523-5.
183. Daniels RJ. Serotonin syndrome due to venlafaxine overdose. J Accid Emerg Med 1998;15:333-7.
184. Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520-6.
185. Kolecki P. Isolated venlafaxine-induced serotonin syndrome. J Emerg Med 1997;15:491-3.
186. Rosebush PI, Margetts P, Mazurek MF. Serotonin syndrome as a result of clomipramine monotherapy. J Clin Psychopharmacother 1999;19:285-7.
187. Stork CM. Serotonin reuptake inhibitors and atypical antidepressants. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfranks toxicologic emergencies. 7th ed. New York: McGraw-Hill, 2002:868-9.
188. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-19.
189. Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Acad Emerg Med 1994;1:330-9.
190. Richard A Lange MD, L David Hillis MD. Cardiovascular complications of cocaine use. N Engl J Med 2001;345:351-8.
191. Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999;99:2737-41.
192. Longe RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989;321:1557-62.
193. Flores ED, Lange RA, Cigarroa RG, et al. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses. J Am Coll Cardiol 1990;16:74-9.
194. Moliterno DJ, Willard JE, Lange RA, et al. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med 1994;330:454-9.
195. Rezkalla SH, Mazza JJ, Kloner RA, et al. Effects of cocaine on human platelets in healthy subjects. Am J Cardiol 1993;72:243-6.
196. Kugelmass AD, Oda A, Monahan K, et al. Activation of human platelets by cocaine. Circulation 1993;88:876-83.
197. Rinder HM, Ault KA, Jatlow PI, et al. Platelet alpha-granule release in cocaine users. Circulation 1994;90:1162-7.
198. Kolodgie FD, Virmani R, Cornhill JF, et al. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol 1991;17:1553-60.
199. Kolodgie FD, Wilson PS, Mergner WJ, et al. Cocaine-induced increase in the permeability function of human vascular endothelial cell monolayers. Exp Mol Pathol 1999;66:109-22.
200. Gan X, Zhang L, Berger O, et al. Cocaine enhances brain endothelial adhesion molecules and leukocyte migration. Clin Immunol 1999;91:68-76.
201. Gitter MJ, Goldsmith SR, Dunbar DN, et al. Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med 1991;115:277-82.
202. Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998;135:245-52.
203. Longe RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990;112:897-903.
204. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. 8. Advanced challenges in resuscitation. 2. Toxicology in ECC. Circulation 2000;102:1-223.
205. ACLS. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. 6. Advanced cardiovascular life support. 1. Introduction to ACLS 2000: overview of recommended changes in ACLS from the Guidelines 2000 conference, Circulation 2000;102:1-86. 216